Wednesday, July 8, 2026

Patent intelligence · US

US 11975106

Uses of halogenated xanthenes in oncology and virology

granted A61KA61K2039/55511A61K31/35A61K31/352
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 18
Applicant portfolio 29
Patent details — US 11975106
Jurisdiction
US
Status
granted
Grant date
May 7, 2024
Expiration
May 2, 2044
Claims
25
CPC classes
A61K, A61K2039/55511, A61K31/35, A61K31/352
View on Google Patents ↗

Quick answer

US 11975106 (Uses of halogenated xanthenes in oncology and virology) is held by Provectus Pharmatech, Inc.. Status: granted. Granted May 7, 2024. Expires May 2, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
25
CPC classes
A61K, A61K2039/55511, A61K31/35, A61K31/352, A61K31/706, A61K39/39

More from Provectus Pharmatech, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12377068

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Expires Jul 31, 2045

    granted
  2. US 12133840

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. · Expires Oct 31, 2044

    granted
  3. US 12064507

    Composition and method for oral treatment of leukemia

    Provectus Pharmatech, Inc. · Expires Aug 15, 2044

    granted
  4. US 11974980

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Provectus Pharmatech, Inc. · Expires May 2, 2044

    granted
  5. US 11938182

    Halogenated xanthenes as vaccine adjuvants

    Provectus Pharmatech, Inc. · Expires Mar 21, 2044

    granted
  6. US 11426379

    Combination of local and systemic therapies for enhanced treatment of dermatologic conditions

    Provectus Pharmatech, Inc. · Expires Aug 25, 2042

    granted
  7. US 11419844

    Halogenated xanthene composition and method for treating hematologic cancers

    Provectus Pharmatech, Inc. · Expires Aug 18, 2042

    granted

Frequently asked questions

What is US patent 11975106?

US 11975106 (Uses of halogenated xanthenes in oncology and virology) is held by Provectus Pharmatech, Inc.. Status: granted. Granted May 7, 2024. Expires May 2, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11975106?

Provectus Pharmatech, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 29 pharmaceutical patents for this assignee.

When does US 11975106 expire?

Our index shows an expiration date of May 2, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.